Investigating the role of IL-1R1 in heart disease progression
Official title: IL-1R1 in Endothelial-to-Mesenchymal Activation
Funded at University of Nebraska Medical Center · NIH-11248621 · Data updated 2026-11-12
This study is looking at how certain changes in blood vessels can lead to heart problems like atherosclerosis, and it’s trying to find ways to help people who have had heart issues by focusing on a specific protein that might make a difference.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | March 1, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $410,370 |
| NIH project number | 7R01HL172846-02 |
| Project ID | NIH-11248621 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with atherosclerosis or those who have experienced an acute myocardial infarction.
✕Less likely to help
Patients without a history of cardiovascular disease or those with non-atherosclerotic conditions may not benefit from this research.
What this research studies
This research focuses on understanding how endothelial-to-mesenchymal transition (EndMT) contributes to the development of atherosclerosis, a condition that can lead to heart attacks. The study examines the relationship between disturbed blood flow and interleukin-1 signaling in promoting EndMT, which is linked to the severity of atherosclerosis. By exploring the role of a specific protein, IRAK1, in this process, the research aims to identify potential therapeutic targets that could improve patient outcomes after heart-related events.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce the risk of heart attacks and improve survival rates for patients with atherosclerosis.
How similar studies have gone: Previous studies have shown promising results with similar approaches, particularly in targeting interleukin-1 signaling to reduce cardiovascular events.
Where this research is happening
-
University of Nebraska Medical Center
Omaha, United States Active
Researchers
- Principal investigator: Alfaidi, Mabruka — University of Nebraska Medical Center
- Study coordinator: Alfaidi, Mabruka
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.